{"id":"W4410290285","doi":"10.1093/ecco-jcc/jjaf080","title":"Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis","year":2025,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"Genentech; Medac; Bristol-Myers Squibb Canada; Nordic Pharma Group; Eisai; Celltrion; Kissei; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Celltrion Healthcare; Astellas Pharma; Mylan; Biogen; EA Pharma Co., Ltd.; Gilead Sciences; Seres Therapeutics; Amgen; Kyorin Pharmaceutical; Pfizer","keywords":"Medicine; Ulcerative colitis; Inflammatory bowel disease; Clinical endpoint; Placebo; Internal medicine; Gastroenterology; Randomized controlled trial; Adverse effect; Colitis; Phases of clinical research; Crohn's disease; Clinical trial; Psoriasis; Immunology; Disease; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006420992,0.001689507,0.004378367,0.0006158639,0.0007072396,0.001491388,0.0009785934,0.00244468,0.003319164],"category_scores_gemma":[0.004140424,0.0009508038,0.004407045,0.0006699108,0.001364252,0.001460604,0.0006015609,0.002746606,0.0005214138],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001433179,"about_ca_system_score_gemma":0.001670847,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007669031,"about_ca_topic_score_gemma":0.002766331,"domain_scores_codex":[0.9968185,0.001922266,0.0003005389,0.0004149811,0.0002597492,0.0002839363],"domain_scores_gemma":[0.9964041,0.00112011,0.001139811,0.0002955241,0.0002671884,0.0007733862],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9547831,0.0069895,0.00234683,0.00108421,0.003263718,0.00007594102,0.0001198718,0.0005697014,0.004472299,0.00005452811,0.0008405315,0.02539973],"study_design_scores_gemma":[0.8983486,0.09059267,0.007096762,0.00005913325,0.001691745,0.0001144098,0.0000339723,0.0003603605,0.00075256,0.00008281832,0.0008346707,0.00003244925],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9761813,0.01609692,0.0009275458,0.0006140109,0.0002818751,0.003218542,0.001368036,0.0001202335,0.001191517],"genre_scores_gemma":[0.9859373,0.004821376,0.001802695,0.0009299337,0.0003396282,0.00336124,0.001729576,0.00003739883,0.001040918],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006420992,"threshold_uncertainty_score":0.03395784,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01266118477218858,"score_gpt":0.2612596747015777,"score_spread":0.2485984899293892,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}